Abstract 4064
Background
The treatment for haematological malignancies is lengthy, complex and intense, leading to potentially debilitating symptoms and reduced health-related quality of life. Patients are living longer due to advancements in early detection and significant improvements in treatment. While treatments for haematological malignancies dramatically increase survivability, many patients suffer from debilitating side effects during and following their treatment. Survivors can suffer long-term effects of both treatment and disease. They may be left with permanent, often devastating, physical impairments leading to an increased risk of other illnesses or a lower quality of life. The presentation is part of a mixed methods study and aims to deepen our understanding of the quality of lives of survivors of adult haematological malignancy. The study will contribute to the under-researched topic related to adult survivors of a haematological malignancy.
Methods
The participants (n = 11) were adults who had completed treatment for a haematological malignancy and were between 1-5 years post-treatment. A qualitative research process of inquiry was used to explore the quality of lives of survivors of haematological malignancy. In-depth face-to-face semi-structured interviews were conducted, based on the content and structure of the interviews envisaged being grounded in the findings of the quantitative phase of the study.
Results
Four themes and several subthemes were generated and reviewed from the qualitative data analysis. The key themes identified in this cohort were:(1) Physical wellbeing (2) Psychological wellbeing (3) Independence and (4) Supportive care needs.
Conclusions
Enhancing these survivors’ physical, psychological wellbeing, an understanding of what independence means to them and addressing supportive care needs can optimise their QoL. Knowledge and understanding of these factors and addressing these needs may provide an insight into implementation measures to enhance the same.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Royal Bournemouth Hospital and Bournemouth University.
Funding
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract